SC 13G/A: SANGAMO THERAPEUTICS, INC
Ticker: SGMO · Form: SC 13G/A · Filed: Aug 16, 2024 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | SC 13G/A |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by SANGAMO THERAPEUTICS, INC.
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Sangamo Therapeutics, Inc (ticker: SGMO) to the SEC on Aug 16, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti).
How long is this filing?
Sangamo Therapeutics, Inc's SC 13G/A filing is 2 pages with approximately 711 words. Estimated reading time is 3 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 7.7 · Accepted 2024-08-16 18:40:25
Key Financial Figures
- $0.01 — INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securiti
Filing Documents
- d853462dsc13ga.htm (SC 13G/A) — 39KB
- 0001193125-24-202234.txt ( ) — 41KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct. BIOGEN INC. By: /s/ Michael Dambach Name: Michael Dambach Title: Treasurer BIOGEN MA INC. By: /s/ Michael Dambach Michael Dambach Treasurer Date: August 16, 2024